Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Envoy Medical's Cash from Operations fell 6511.63% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 2664.67%. This contributed to the annual value of -$17.9 million for FY2024, which is 502.02% down from last year.
  • According to the latest figures from Q3 2025, Envoy Medical's Cash from Operations is -$4.3 million, which was down 6511.63% from -$4.5 million recorded in Q2 2025.
  • Envoy Medical's Cash from Operations' 5-year high stood at $1.1 million during Q3 2023, with a 5-year trough of -$11.1 million in Q4 2023.
  • Over the past 4 years, Envoy Medical's median Cash from Operations value was -$4.0 million (recorded in 2023), while the average stood at -$3.8 million.
  • Examining YoY changes over the last 5 years, Envoy Medical's Cash from Operations showed a top increase of 12092.1% in 2023 and a maximum decrease of 90810.43% in 2023.
  • Envoy Medical's Cash from Operations (Quarter) stood at -$2.4 million in 2022, then crashed by 368.47% to -$11.1 million in 2023, then skyrocketed by 54.32% to -$5.1 million in 2024, then increased by 14.93% to -$4.3 million in 2025.
  • Its Cash from Operations stands at -$4.3 million for Q3 2025, versus -$4.5 million for Q2 2025 and -$3.7 million for Q1 2025.